Skip to Content

Notice

Agency Information Collection Activities: Proposed Collection; Comment Request; Guidance for Industry on How to Use E-Mail to Submit a Request for a Meeting or Teleconference to the Office of New Animal Drug Evaluation

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA).

DATES:

Submit written comments on the collection of information by October 23, 2000.

ADDRESSES:

Submit written comments on the collection of information to Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attention: Desk Officer for FDA.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Denver Presley, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1472.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Guidance for Industry on How to Use E-Mail to Submit a Request for a Meeting or Teleconference to the Office of New Animal Drug Evaluation.

Description: As part of new animal drug development, sponsors often meet with the Center for Veterinary Medicine (CVM), scientists to formulate a rational approach for studies to be conducted, and to discuss how they meet the statutory requirements for new animal drug approval under section 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b). Requests for meetings and teleconferences about new animal drug submissions are currently submitted to CVM on paper. CVM is responsible for developing and administering a guidance that explains how to adhere to the Electronic Records; Electronic Signatures regulations (21 CFR part 11). These regulations provide for the voluntary submission of parts or all of regulatory records in electronic format without an accompanying paper copy and complies with the Government Paperwork Elimination Act (GPEA). The GPEA requires Federal agencies, by October 21, 2003, to give persons who are required to maintain, submit, or disclose information, the option of doing so electronically, when practical, as a substitute for paper.

This guidance document describes the procedure for persons who are new animal drug sponsors who wish to submit a request for a meeting or teleconference to the Office of New Animal Drug Evaluation by e-mail on FDA Form No. 3489. The information sponsors should include on the form are: The sponsor's name and address, a list of requested participants, an indication of audiovisual needs, and an agenda.

Description of Respondents: The likely respondents for this collection of information are sponsors who will be conducting clinical investigations under 21 CFR 511.1(b). In the Federal Register of June 29, 2000 (65 FR 40108), the FDA announced the availability of this guidance as a draft document and requested public comment on the proposed collection of information. No comments were received on the estimated annual reporting burden. We therefore believe the annual reporting burden of 116 hours should remain unchanged.

Table 1.—Estimated Annual Reporting Burden1

Form FDA No.No. of ­RespondentsAnnual ­Frequency per ­ResponseTotal Annual ResponsesHours per ­ResponseTotal Hours
3,489190.881680.69116
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
Start Printed Page 57195

The estimates in table 1 of this document resulted from discussions with new animal drug sponsors. The estimated burden includes requests for meetings or teleconferences submitted by e-mail and on paper.

Start Signature

Dated: September 14, 2000.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

End Signature End Supplemental Information

[FR Doc. 00-24267 Filed 9-20-00; 8:45 am]

BILLING CODE 4160-01-F